ACET
Adicet Bio, Inc.·Healthcare
6.76
1.458%(−0.10)
Market ClosedLast Updated: — ET
52W L: $6.0152W H: $17.44
ACET NEWS
zacks.com
Mar 24
Adicet Bio (ACET) Upgraded to Buy: Here's Why
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
businesswire.com
Mar 12
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025. “Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the.
defenseworld.net
Mar 5
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $69.00
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has
defenseworld.net
Feb 8
Adicet Bio, Inc. (NASDAQ:ACET) Receives $69.00 Consensus PT from Brokerages
Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one
businesswire.com
Jan 30
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York. Details of the event are as follows: Date: Thursday, February 12, 2026 Time: 2:00p.m. ET The l.
defenseworld.net
Jan 20
Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average – What’s Next?
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $11.11 and traded as low as $7.87. Adicet Bio shares last traded at $8.28, with a volume of 137,944 shares. Analyst Upgrades
